Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4560) 4560
Publication (280) 280
Book Review (129) 129
Book Chapter (64) 64
Book / eBook (23) 23
Conference Proceeding (9) 9
Dissertation (7) 7
Data Set (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Magazine Article (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2789) 2789
index medicus (2182) 2182
antithrombotic therapy (1954) 1954
male (1331) 1331
female (1136) 1136
anticoagulants (1076) 1076
aged (905) 905
anticoagulants - therapeutic use (888) 888
atrial fibrillation (880) 880
cardiac & cardiovascular systems (845) 845
warfarin (844) 844
risk factors (831) 831
peripheral vascular disease (792) 792
stroke (777) 777
animals (762) 762
hematology (751) 751
aspirin (714) 714
prevention (688) 688
fibrinolytic agents - therapeutic use (687) 687
middle aged (680) 680
thrombosis (679) 679
pharmacology & pharmacy (671) 671
treatment outcome (532) 532
atrial fibrillation - drug therapy (516) 516
anticoagulants - adverse effects (512) 512
antithrombotic (505) 505
anticoagulation (501) 501
thromboembolism (496) 496
stroke - prevention & control (486) 486
venous thromboembolism (468) 468
anticoagulants - administration & dosage (467) 467
risk (460) 460
antithrombotic agents (457) 457
aged, 80 and over (454) 454
management (449) 449
platelet aggregation inhibitors - therapeutic use (438) 438
administration, oral (419) 419
atrial fibrillation - complications (405) 405
atrial-fibrillation (401) 401
hemorrhage - chemically induced (398) 398
medicine & public health (395) 395
care and treatment (361) 361
medicine, general & internal (340) 340
clopidogrel (334) 334
molecular-weight heparin (332) 332
heparin (331) 331
surgery (325) 325
analysis (322) 322
stroke prevention (321) 321
cardiology (319) 319
bleeding (317) 317
risk assessment (313) 313
risk-factors (313) 313
drug therapy (311) 311
fibrinolytic agents - adverse effects (310) 310
rats (307) 307
retrospective studies (304) 304
mortality (301) 301
fibrinolytic agents - pharmacology (299) 299
adult (298) 298
stroke - etiology (289) 289
warfarin - therapeutic use (280) 280
antithrombotics (279) 279
antiplatelet therapy (276) 276
fibrinolytic agents - administration & dosage (275) 275
dabigatran (272) 272
thrombosis - drug therapy (268) 268
percutaneous coronary intervention (266) 266
anticoagulant (265) 265
therapy (264) 264
rivaroxaban (262) 262
abridged index medicus (261) 261
aspirin - therapeutic use (257) 257
dose-response relationship, drug (257) 257
anticoagulants - pharmacology (250) 250
thrombin (250) 250
deep-vein thrombosis (249) 249
internal medicine (243) 243
antiplatelet (240) 240
drug therapy, combination (238) 238
acute coronary syndromes (235) 235
myocardial-infarction (235) 235
thrombosis - prevention & control (235) 235
factor xa inhibitors (234) 234
thromboembolism - prevention & control (232) 232
acute myocardial-infarction (228) 228
cardiovascular (228) 228
blood coagulation - drug effects (225) 225
hemorrhage (225) 225
oral anticoagulants (225) 225
antithrombotic agent (223) 223
platelet aggregation inhibitors - adverse effects (222) 222
chemistry, medicinal (221) 221
time factors (217) 217
platelet aggregation inhibitors - pharmacology (210) 210
platelet aggregation - drug effects (208) 208
unfractionated heparin (208) 208
platelet aggregation inhibitors - administration & dosage (203) 203
cardiac arrhythmia (202) 202
health aspects (199) 199
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Women's College Hospital - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4411) 4411
French (73) 73
German (65) 65
Japanese (30) 30
Spanish (28) 28
Russian (15) 15
Korean (11) 11
Portuguese (7) 7
Polish (5) 5
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Arabic (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Pharmacology in the catheterization laboratory
by Waksman, Ron and Ajani, Andrew E
2010, ISBN 9781405157049, xv, 379
Book
Details down arrow
2. Full Text Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
by Patrono, C and Bachmann, F and Baigent, C and Bode, C and Caterina, R. de and Charbonnier, B and Fitzgerald, D and Hirsh, J and Husted, S and Kvasnicka, J and Montalescot, G and Garcia Roiguez, L.A and Verheugt, F.W.A and Vermylen, J and Wallentin, L and Priori, S.G and Alonso Garcia, M.A and Blanc, J.J and Budaj, A and Cowie, M and Dean, V and Deckers, J.A and Fernandez Bugos, E and Lekakis, J and Lindahl, B and Mazzotta, G and Steg, P.G and Teixeira, F and Wilcox, R and European Society of Cardiology and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper
European Heart Journal, ISSN 0195-668X, 2004, Volume 25, Issue 2, pp. 166 - 181
ST-ELEVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | LOW-DOSE ASPIRIN | MYOCARDIAL-INFARCTION | OXIDANT STRESS | ANTITHROMBOTIC THERAPY | PLATELET | THROMBOXANE BIOSYNTHESIS | CORONARY HEART-DISEASE | PRIMARY PREVENTION | SECONDARY PREVENTION | Risk Assessment | Humans | Risk Factors | Platelet Aggregation Inhibitors - pharmacology | Clinical Trials as Topic | Coronary Artery Disease - drug therapy | Blood Platelets - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Patient Selection | Human | Platelet Aggregation Inhibitors/pharmacology/therapeutic use | Coronary Arteriosclerosis/drug therapy | Clinical Trials | Blood Platelets/drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association
by Furie, KL and Goldstein, LB and Albers, GW and Khatri, P and Neyens, R and Turakhia, MP and Turan, TN and Wood, KA and Council Cardiovasc Nursing and Amer Heart Assoc Stroke Council and Council Peripheral Vasc Dis and Council Quality Care Outcomes Res and Council Clinical Cardiology and Council on Cardiovascular Nursing and Council on Peripheral Vascular Disease and Council on Quality of Care and Outcomes Research and American Heart Association Stroke Council and Council on Clinical Cardiology
STROKE, ISSN 0039-2499, 12/2012, Volume 43, Issue 12, pp. 3442 - 3453
PREDICTING STROKE | treatment | COST-EFFECTIVENESS | TRANSIENT ISCHEMIC ATTACK | RISK STRATIFICATION | antithrombotic therapy | RANDOMIZED EVALUATION | CLINICAL NEUROLOGY | AHA Scientific Statements | ANTICOAGULATION THERAPY | atrial fibrillation | DABIGATRAN ETEXILATE | WARFARIN | PERIPHERAL VASCULAR DISEASE | NORMALIZED RATIO CONTROL | SUBGROUP ANALYSIS | stroke prevention | American Heart Association | Stroke - prevention & control | Administration, Oral | Atrial Fibrillation - drug therapy | Heart Valves | United States | Fibrinolytic Agents - therapeutic use | Humans | Atrial Fibrillation - etiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Acute coronary syndromes
by Topol, Eric J., 1954
1998, ISBN 9780824701406, x, 628
diagnosis | Myocardial Infarction | Fibrinolytic Agents | Coronary heart disease | therapeutic use | therapy
Book
Details down arrow
5. Antithrombotic Reversal Agents
by Wilson, MD and Davis, JE
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, ISSN 0889-8588, 12/2017, Volume 31, Issue 6, pp. 1147 - 1147
The actively bleeding anticoagulated patient presenting to the emergency department requires rapid evaluation and treatment, which is made increasingly... 
Reversal options | ED AMERICAN-COLLEGE | MANAGEMENT | THROMBOSIS | PREVENTION | Bleeding | Coagulopathic | ANTICOAGULATION | CLINICAL-PRACTICE GUIDELINES | Anticoagulate | Emergency department | THERAPY | ONCOLOGY | WARFARIN | PHARMACOLOGY | Antithrombotic reversal agent | VITAMIN-K | HEMATOLOGY | Hemorrhage - therapy | Fibrinolytic Agents - therapeutic use | Humans | Anticoagulants - therapeutic use | Emergency Medical Services - methods | Hemorrhage - chemically induced | Anticoagulants - adverse effects | Hemorrhage - diagnosis
Journal Article
Details down arrow
6. Full Text Utilization of Anticoagulant and Antiplatelet Agents Among Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　― Retrospective Cohort Study Using a Nationwide Claims Database in Japan
by Ono, Fumiko and Tanaka, Shiro and Nakao, Yoko M and Kawakami, Koji
Circulation Journal, ISSN 1346-9843, 2018, Volume 82, Issue 2, pp. 361 - 368
Background:The European Society of Cardiology recommends a risk-based antithrombotic strategy for patients with atrial fibrillation (AF) who undergo... 
Percutaneous coronary intervention | Antithrombotic therapy | Atrial fibrillation | Japan | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | METAANALYSIS | GUIDELINES | RISK | ASPIRIN | STROKE | STENT IMPLANTATION | THERAPY | CLOPIDOGREL | DISEASE | Risk Assessment | Atrial Fibrillation - therapy | Humans | Anticoagulants - therapeutic use | Male | Incidence | Asian Continental Ancestry Group | Stroke - etiology | Aged, 80 and over | Female | Aged | Retrospective Studies | Platelet Aggregation Inhibitors - therapeutic use | Percutaneous Coronary Intervention | Databases, Factual
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor
by PERZBORN, E and STRASSBURGER, J and WILMEN, A and POHLMANN, J and ROEHRIG, S and SCHLEMMER, K‐H and STRAUB, A
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2005, Volume 3, Issue 3, pp. 514 - 521
BAY 59‐7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis. BAY 59‐7939... 
antithrombotic activity | oral anticoagulant | Factor Xa inhibitor | Oral anticoagulant | Antithrombotic activity | RATS | ANTICOAGULANT | DX-9065A | EXPERIMENTAL THROMBOSIS | ARGATROBAN | ARTERIAL | POTENT | MODELS | PERIPHERAL VASCULAR DISEASE | factor Xa inhibitor | HEMATOLOGY | ACTIVE INHIBITOR | Rabbits | Factor Xa Inhibitors | Species Specificity | Venous Thrombosis - drug therapy | Humans | Morpholines - pharmacology | Rats | Dose-Response Relationship, Drug | Serine Proteinase Inhibitors - therapeutic use | Fibrinolytic Agents - pharmacology | Rivaroxaban | Animals | Thiophenes | Fibrinolytic Agents - therapeutic use | Blood Coagulation Tests | Inhibitory Concentration 50 | Venous Thrombosis - prevention & control | Thromboplastin - metabolism | Serine Proteinase Inhibitors - pharmacology | Disease Models, Animal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Thromboembolic disease and antithrombotic agents in the elderly
by Jacobs, Laurie G
2006, Clinics in geriatric medicine, ISBN 1416035001, Volume 22 no. 1., xiv, 219
Anticoagulants (Medicine) | Thromboembolism | Older people | Fibrinolytic agents | Thrombolytic therapy | Diseases
Book
Details down arrow
9. Full Text Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?
by Huber, Kurt, MD and Bates, Eric R., MD and Valgimigli, Marco, MD, PhD and Wallentin, Lars, MD, PhD and Kristensen, Steen Dalby, MD, DMSc and Anderson, Jeffrey L., MD and Lopez Sendon, Jose Luis, MD and Tubaro, Marco, MD and Granger, Christopher B., MD and Bode, Christoph, MD and Ohman, Erik Magnus, MD and Steg, Philippe Gabriel, MD and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Heparin-induced thrombocytopenia
by Warkentin, Theodore E., 1960 and Greinacher, Andreas
2000, Fundamental and clinical cardiology, ISBN 9780824702717, Volume 39, xix, 400
Thrombocytopenia | adverse effects | Anticoagulants | chemically induced | Heparin | therapeutic use
Book
Details down arrow
11. Full Text Guideline on the management of bleeding in patients on antithrombotic agents
by Makris, Mike and Veen, Joost J and Tait, Campbell R and Mumford, Andrew D and Laffan, Mike and British Comm Stand Haematology and British Committee for Standards in Haematology and The British Committee for Standards in Haematology
British Journal of Haematology, ISSN 0007-1048, 01/2013, Volume 160, Issue 1, pp. 35 - 46
reversal | bleeding | anticoagulant | antiplatelet | antithrombotic | Reversal | Antiplatelet | Anticoagulant | Bleeding | Antithrombotic | PLATELET-FUNCTION | RECOMBINANT FACTOR VIIA | HEPARIN-INDUCED THROMBOCYTOPENIA | CARDIOPULMONARY BYPASS | ACTIVATED FACTOR-VII | THROMBIN GENERATION | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | ACUTE MYOCARDIAL-INFARCTION | HEMATOLOGY | THROMBOLYTIC THERAPY | Fibrinolytic Agents - adverse effects | Guidelines as Topic | Hemorrhage - drug therapy | Fibrinolytic Agents - administration & dosage | Humans | Anticoagulants (Medicine) | Cardiovascular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Use of Antithrombotic Agents During Pregnancy
by Bates, Shannon M and Greer, Ian A and Hirsh, Jack and Ginsberg, Jeffrey S
Chest, ISSN 0012-3692, 09/2004, Volume 126, Issue 3, pp. 627S - 644S
This chapter about the use of antithrombotic agents during pregnancy is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy:... 
low molecular weight heparin | unfractionated heparin | obstetrics | antithrombotic | pregnancy | SYSTEMIC-LUPUS-ERYTHEMATOSUS | VENOUS THROMBOEMBOLIC DISEASE | ANTIPHOSPHOLIPID ANTIBODIES | DEEP-VEIN THROMBOSIS | FACTOR-V-LEIDEN | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | PROTEIN-C RESISTANCE | CRITICAL CARE MEDICINE | Pregnancy | Practice | Research | Heparin | Complications | Obstetrics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Thrombolytic Agents: Thrombosis‐Responsive Thrombolytic Coating Based on Thrombin‐Degradable Tissue Plasminogen Activator (t‐PA) Nanocapsules (Adv. Funct. Mater. 45/2017)
by Li, Cong and Du, Hui and Yang, Aizhen and Jiang, Shuaibing and Li, Zhenhua and Li, Dan and Brash, John L and Chen, Hong
Advanced Functional Materials, ISSN 1616-301X, 12/2017, Volume 27, Issue 45, p. n/a
In article number 1703934, Dan Li, Hong Chen, and co‐workers report a novel thrombolytic coating whose activity is triggered by thrombosis. The coated surfaces... 
fibrinolysis | nanocapsules | coating | antithrombotic materials | thrombin‐responsive materials | Thrombin | Coatings | Tissue plasminogen activator | Thrombosis | Blood clot
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis
by Fanaroff, Alexander C and Hasselblad, Victor and Roe, Matthew T and Bhatt, Deepak L and James, Stefan K and Steg, Ph Gabriel and Gibson, C Michael and Ohman, E Magnus and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Uppsala universitet and Institutionen för medicinska vetenskaper
International Journal of Cardiology, ISSN 0167-5273, 2016, Volume 241, pp. 87 - 96
Abstract Background Nine oral antithrombotic medications currently available in the United States and Europe have been studied in clinical trials for secondary... 
Cardiovascular | Antiplatelet agents, antithrombotic agents | Network meta-analysis | Acute coronary syndrome | Acute myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | TICAGRELOR | SAFETY | RIVAROXABAN | RANDOMIZED-TRIAL | ASPIRIN | CLOPIDOGREL | DUAL ANTIPLATELET THERAPY | RECURRENT MYOCARDIAL-INFARCTION | INTERVENTION | ARTERY-DISEASE | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - epidemiology | Hemorrhage - epidemiology | Administration, Oral | Humans | Acute Coronary Syndrome - diagnosis | Fibrinolytic Agents - administration & dosage | Clinical Trials as Topic - methods | Hemorrhage - chemically induced | Secondary Prevention - methods | Acute Coronary Syndrome - prevention & control | Hemorrhage - diagnosis | Coronary heart disease | Analysis | Cardiovascular agents | Medical research | Aspirin | Mortality | Medicine, Experimental | Cardiology | antiplatelet agents | antithrombotic agents | acute coronary syndrome | network meta-analysis | acute myocardial infarction | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Antiplatelet agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Managing antithrombotic agents during endoscopy
by Greenwald, David A., MD
Best Practice & Research: Clinical Gastroenterology, ISSN 1521-6918, 2016, Volume 30, Issue 5, pp. 679 - 687
Abstract Antithrombotic agents are used widely to reduce the risks of thromboembolic events in patients with a variety of cardiovascular and other conditions.... 
Gastroenterology and Hepatology | Antithrombotic agents | Anticoagulants | Endoscopy | Antiplatelet agents | MANAGEMENT | CHADS-VASC SCORE | ATRIAL-FIBRILLATION | THERAPY | STROKE RISK | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | CHADS SCORE | GASTROINTESTINAL ENDOSCOPY | COMPLICATIONS | GASTROENTEROLOGY & HEPATOLOGY | Perioperative Care | Anticoagulants - administration & dosage | Thromboembolism - prevention & control | Humans | Platelet Aggregation Inhibitors - administration & dosage | Endoscopy, Gastrointestinal | Fibrinolytic Agents - administration & dosage | Cardiovascular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Combining antithrombotic and fibrinolytic agents: Can it be done?
by Khatri, Pooja and Mono, Marie-Luise
Stroke, ISSN 0039-2499, 05/2013, Volume 44, Issue 5, pp. 1489 - 1491
thrombolysis | antiplatelet agent | stroke | antithrombotic | MULTICENTER | TISSUE-PLASMINOGEN ACTIVATOR | RECANALIZATION | CLINICAL NEUROLOGY | TRIAL | THERAPY | PREDICTORS | ACUTE ISCHEMIC-STROKE | ARTERIAL REOCCLUSION | POOLED ANALYSIS | PERIPHERAL VASCULAR DISEASE | Clinical Trials as Topic | Stroke - drug therapy | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Humans | Thrombolytic Therapy - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights